Zai Lab Announces Participation in September Investor Conferences

Rhea-AI Summary

On August 23, 2022, Zai Lab Limited (NASDAQ: ZLAB) announced participation in several investor conferences in September. These include the 5th HKEX Biotech Summit on September 1, Citi’s 17th Annual BioPharma Conference on September 8, and others in New York. The events will feature presentations and panel discussions aimed at advancing their mission to provide transformative medicines. Zai Lab operates in oncology, autoimmune disorders, infectious diseases, and neurological disorders, focusing on improving global human health.

Positive

• Participation in multiple high-profile investor conferences enhances visibility and investor engagement.
• Focus on transformative medicines in critical health areas may attract positive market interest.

Negative

• None.

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in September:

5th HKEX Biotech Summit 2022
Panel Discussion: Thursday, September 1, 2022, 3:10 p.m. HKT
Location: Hong Kong

Citi’s 17th Annual BioPharma Conference
Fireside Chat: Thursday, September 8, 2022, 8:50 a.m. ET
Location: Boston, MA

3rd Annual Jefferies Asia Forum
Presentation: Friday, September 9, 2022, 11:00 a.m. HKT

Morgan Stanley 20th Annual Global Healthcare Conference
Meetings: Wednesday, September 14, 2022
Location: New York

Cantor Oncology, Hematology & HemeOnc Conference
Meetings: Wednesday, September 28, 2022
Location: New York

Webcast links of the presentations will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. The archived replay will be viewable after the events for 90 days.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

Investor Relations: Lina Zhang
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media: Danielle Halstrom / Xiaoyu Chen
+1 (215) 280-3898 / +86 185 0015 5011
danielle.halstrom@zailaboratory.com / xiaoyu.chen@zailaboratory.com 

Zai Lab Limited

Source: Zai Lab Limited

FAQ

What conferences will Zai Lab participate in September 2022?

Zai Lab will participate in the 5th HKEX Biotech Summit, Citi’s 17th Annual BioPharma Conference, the 3rd Annual Jefferies Asia Forum, Morgan Stanley 20th Annual Global Healthcare Conference, and Cantor Oncology, Hematology & HemeOnc Conference.

What is the significance of Zai Lab's participation in investor conferences?

Participation in investor conferences allows Zai Lab to enhance visibility, engage with investors, and potentially attract investment in their biopharmaceutical initiatives.

When will Zai Lab participate in the HKEX Biotech Summit?

Zai Lab will participate in the HKEX Biotech Summit on September 1, 2022, at 3:10 p.m. HKT.

What is Zai Lab's focus in the biopharmaceutical industry?

Zai Lab focuses on developing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders.